Clinical trials: Preventive Intervention
Aortic Dissection
False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study (FLAGSHIP_FRA)
To determine the safety and feasibility of investigational product to reduce aortic dissection false lumen perfusion.
- Trial name
- FLAGSHIP_FRA (NCT06740721)
- Testing
- False Lumen Embolization System, IMPEDE-FX RapidFill
- Volunteers
- 15 people
- Sponsor
- Shape Memory Medical, Inc.
Venous Thromboembolism
Eliquis Regulatory Post Marketing Surveillance (rPMS)
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about…
- Trial name
- NCT01885585
- Testing
- Apixaban
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have a tube placed in a vein to receive treatment (called Peripherally Inserted…
- Trial name
- ROXI-PEAK (NCT07697599)
- Testing
- REGN7508, REGN9933
- Where
- Georgia
- Volunteers
- 1,908 people
- Sponsor
- Regeneron Pharmaceuticals
Meningococcal Disease
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.
- Trial name
- NCT01139021
- Testing
- rMenB+OMV NZ
- Where
- 19 sites in Czechia, Finland
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Hypercholesteremia
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
- Trial name
- NCT00347217
- Where
- 215 sites in Netherlands
- Volunteers
- 3,840 people
- Sponsor
- AstraZeneca
Influenza, Human
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza…
- Trial name
- NCT01390792
- Testing
- Zanamivir hydrate
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Surgical Site Infection
Air Barrier System for the Prevention of Surgical Site Infection
Airborne particles are present in all indoor environments including the operating room. Most of these particles come from the surgical staff moving around in the room, positioning of the patient during surgery, and the movement…
- Trial name
- ABS (NCT01610271)
- Testing
- Air Barrier System
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Nimbic Systems, LLC
Keloid
A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids
This pilot study will assess the safety and efficacy of Apligraf in the healing and recurrence of keloids post surgical shave excision in patients with clinically diagnosed keloids.
- Trial name
- NCT00587587
- Testing
- Apligraf, Standard dressing regimen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Organogenesis
Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation
OPTION-EMEA Clinical Trial
The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with…
- Conditions
- Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Pulsed Field Ablation
- Trial name
- OPTION-EMEA (NCT07349121)
- Testing
- Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case, Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure
- Where
- 11 sites in Belgium, Croatia and 3 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Zika Virus, Zika Virus Infection
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated…
- Trial name
- NCT03425149
- Testing
- VLA1601
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Pandemic Influenza, Prevention
Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
A single center, randomized and double-blind phase II clinical trial is to be conducted in adults to evaluate the safety and immunogenicity of an inactivated pandemic influenza vaccine (whole-virion, aluminium-adjuvanted).
- Trial name
- NCT00535665
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Acute Wound
Cleanser for Acute Wounds
The proposed study will be a prospective trial of management of acute traumatic wounds (less than 24 hours from injury and without previous intervention aside from a dressing for coverage).
- Trial name
- NCT05422144
- Testing
- Antimicrobial Skin & Wound Cleanser (AWC), Antimicrobial Wound Gel (AWG)
- Where
- United States
- Sponsor
- Rochal Industries LLC
Pressure Ulcer, Pressure Injury
Usability Validation of Patient Monitoring Device for Pressure Injury Prevention and Fall Detection
This study describes a procedure to collect a subject's position, movement, physiological data and usability information using Masimo's investigational device.
- Conditions
- Pressure Ulcer, Pressure Injury, Falls Injury
- Trial name
- NCT03121144
- Testing
- Masimo Centroid System
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Masimo Corporation
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness at UPMC
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR-C19 UPMC (NCT05667116)
- Testing
- EVUSHELD
- Where
- United States
- Volunteers
- 4,232 people
- Sponsor
- AstraZeneca
Rabies
Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children…
- Trial name
- NCT00708084
- Testing
- CL184, HRIG
- Where
- Philippines
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Neoplasms, Prostate, Benign Prostatic Hyperplasia
Economic Analyses of the REDUCE Trial
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial.
- Conditions
- Neoplasms, Prostate, Benign Prostatic Hyperplasia, Cancer
- Trial name
- NCT01337258
- Testing
- Dutasteride
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Antibody Mediated Rejection
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization…
- Trial name
- NCT01399593
- Testing
- Eculizumab
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute Gastroenteritis
Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)
The purpose of the research is to evaluate the safety and tolerability of the tetravalent recombinant Norovirus vaccine at different doses, to initially explore the immunogenicity of the vaccine, and to determine the appropriate…
- Trial name
- NCT04563533
- Testing
- Low-dose vaccine, High-dose vaccine
- Where
- China
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Pneumonitis, SARS-CoV Infection
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
- Trial name
- NCT04590547
- Testing
- GLS-1027
- Where
- 17 sites in United States, Bulgaria and 3 more
- Volunteers
- 132 people
- Sponsor
- GeneOne Life Science, Inc.
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
PROPACT: Retrospective Prophylaxis Patient Case Collection
This study is conducted in Europe and North and South America. The primary aim of this observational study is to evaluate the frequency and pattern of bleeding episodes in haemophilia patients receiving preventative treatment…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- PROPACT (NCT00882778)
- Testing
- eptacog alfa (activated)
- Where
- 14 sites in United States, Argentina and 12 more
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S